A unique two-excipient heat stable tablet formulation of oral insulin: preliminary results

preprint OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View at publisher

Abstract

We report a novel formulation approach for development of a thermostable oral insulin tablet. Using freeze drying to form a heat stable tablet in a single-step process, we demonstrate hydroxypropyl beta cyclodextrin (HP-β-CD) encapsulated lipophilic ion-pair complex of insulin using bile salt achieves intestinal absorption and sustained glucose levels. The tablets produced using this simple approach with only two excipients offer protection from enzymatic and stomach acid degradation and facilitate insulin uptake, without any need for specialized drug manufacturing or enteric coating. Insulin in this innovative formulation is thermotolerant, capable of maintaining stability even under heat stress at 30-40°C/65-75% RH. The convenient presentation of insulin as a thermostable oral tablet presents a low-cost scalable manufacturing method that simplifies the logistics of storage, transport, and distribution in any setting, including areas where cold storage maybe limited or unavailable. Graphical Abstract Our unique formulation approach protects insulin from stomach and temperature induced degradation, improves intestinal permeability providing a sustained release of insulin for glycemic control. The freeze dried tablet product format is easily scalable and flexible, increasing accessibility across all populations.
Full text 1,084 characters · extracted from oa-html · click to expand
Abstract We report a novel formulation approach for development of a thermostable oral insulin tablet. Using freeze drying to form a heat stable tablet in a single-step process, we demonstrate hydroxypropyl beta cyclodextrin (HP-β-CD) encapsulated lipophilic ion-pair complex of insulin using bile salt achieves intestinal absorption and sustained glucose levels. The tablets produced using this simple approach with only two excipients offer protection from enzymatic and stomach acid degradation and facilitate insulin uptake, without any need for specialized drug manufacturing or enteric coating. Insulin in this innovative formulation is thermotolerant, capable of maintaining stability even under heat stress at 30-40°C/65-75% RH. The convenient presentation of insulin as a thermostable oral tablet presents a low-cost scalable manufacturing method that simplifies the logistics of storage, transport, and distribution in any setting, including areas where cold storage maybe limited or unavailable. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-23T02:00:01.238055+00:00
License: CC-BY-4.0